{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:58:47Z","timestamp":1790657927444,"version":"4.1.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Letermovir is an antiviral agent approved for CMV infection prophylaxis in transplant recipients. This study aimed to evaluate safety signals reported during letermovir treatment, using data from the FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from October 2017 to September 2024 were extracted from FAERS database. Reported events were analyzed across hierarchy levels, from Preferred Term (PT) to High-Level Terms (HLTs) and System Organ Classes (SOCs). Disproportionality analysis was performed to detect safety signals. Recorded time to onset was analyzed descriptively, and univariable logistic regression was performed to explore report-level factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most frequently reported events was infections and infestations at SOC level, cytomegalovirus infection at HLT level and CMV infection reactivation at Preferred Term level. Apart from CMV-related events, safety signals involved hematological abnormalities, pericardial effusion, hepatic and renal failure, bacterial and viral infections, pathogen resistance, and transplantation-related events. The median recorded time to onset was 25 days for all events, and 33 days for CMV-related events, with later recorded onset in intravenous than tablet reports. Exploratory logistic regression showed lower odds of CMV-related event reporting with older age and treatment initiation in more recent years, higher odds with intravenous administration, and regional differences in reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified safety signals reported with letermovir involving hematological, cardiac, hepatic, renal, infectious, and transplantation-related events. CMV-related signals may reflect breakthrough infection. These findings require validation in clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1935778","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:39:30Z","timestamp":1790656770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety signals and CMV-related events reported during letermovir therapy: a FAERS database study"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhangjie","family":"Chen","sequence":"first","affiliation":[{"name":"Tianjin Institutes of Health Science, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuning","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Zhen","sequence":"additional","affiliation":[{"name":"Tianjin Institutes of Health Science, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Tianjin, China"]},{"name":"Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Institutes of Health Science, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Tianjin Institutes of Health Science, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[{"name":"Tianjin Institutes of Health Science, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cld.2020.08.008","article-title":"Cardiac and pulmonary vascular risk stratification in liver transplantation","volume":"25","author":"Aghaulor","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1182\/bloodadvances.2022009376","article-title":"CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia","volume":"7","author":"Akahoshi","year":"2023","journal-title":"Blood Adv."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1093\/jac\/dkaa135","article-title":"Letermovir breakthroughs during the French named patient programme: interest of monitoring blood concentration in clinical practice","volume":"75","author":"Alain","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e13166","DOI":"10.1111\/tid.13166","article-title":"Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients","volume":"21","author":"Aryal","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/cpdd.1081","article-title":"Pharmacokinetics, safety, and tolerability of letermovir following Single- and multiple-dose administration in healthy Japanese subjects","volume":"11","author":"Asari","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/jcrt.JCRT_314_17","article-title":"Cardiac complications in patients who underwent to hematopoietic stem cell transplantation","volume":"16","author":"Ata\u015f","year":"2020","journal-title":"J. Cancer Res. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.clml.2019.12.027","article-title":"Cardiotoxicity in hematopoietic stem cell transplant: keeping the beat","volume":"20","author":"Baker","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B8","doi-asserted-by":"publisher","first-page":"105024","DOI":"10.1016\/j.antiviral.2021.105024","article-title":"Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: a case report","volume":"188","author":"Baldo","year":"2021","journal-title":"Antivir. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2215\/CJN.00520121","article-title":"Post-transplant cardiovascular disease","volume":"16","author":"Birdwell","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"13596535221133619","DOI":"10.1177\/13596535221133619","article-title":"Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients","volume":"27","author":"Boignard","year":"2022","journal-title":"Antivir. Therapy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e13627","DOI":"10.1111\/tid.13627","article-title":"Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: a multicenter study from the Spanish hematopoietic transplantation and cell therapy group","volume":"23","author":"Bueno","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","article-title":"Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease","volume":"16","author":"Cantoni","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","volume":"12","author":"El Helou","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e14808","DOI":"10.1111\/ctr.14808","article-title":"Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients","volume":"36","author":"Golob","year":"2022","journal-title":"Clin. Transpl."},{"key":"B17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.chom.2019.11.013","article-title":"Human cytomegalovirus miRNAs regulate TGF-\u03b2 to mediate myelosuppression while maintaining viral latency in CD34(+) hematopoietic progenitor cells","volume":"27","author":"Hancock","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e13515","DOI":"10.1111\/tid.13515","article-title":"Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: a case series and review of the literature","volume":"23","author":"Hofmann","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"B19","volume-title":"PREVYMIS (Letermovir) Prescribing Information","year":""},{"key":"B20","volume-title":"Adverse Events (AE) in Adult HSCT Patients","year":""},{"key":"B21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"B22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-024-01612-y","article-title":"Increased epstein-barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation","volume":"17","author":"Kong","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"62.e1","DOI":"10.1016\/j.jtct.2022.10.005","article-title":"Letermovir as Cytomegalovirus prophylaxis in a pediatric cohort: a retrospective analysis","volume":"29","author":"Kuhn","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"Jama"},{"key":"B25","doi-asserted-by":"publisher","first-page":"85.e1","DOI":"10.1016\/j.bbmt.2020.10.009","article-title":"Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis","volume":"27","author":"Lin","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"B26","first-page":"78","article-title":"Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation","volume":"91","author":"Ljungman","year":"2006","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"14725","DOI":"10.1073\/pnas.1110900108","article-title":"Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection","volume":"108","author":"Lopez-Verg\u00e8s","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1182\/bloodadvances.2021006213","article-title":"Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation","volume":"6","author":"Lorentino","year":"2022","journal-title":"Blood Adv."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1027593","DOI":"10.3389\/fimmu.2022.1027593","article-title":"Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: impact of CMV infection and leukemia relapse","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for Cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/IDR.S79131","article-title":"Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus","volume":"8","author":"Melendez","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"B32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41587-019-0404-8","article-title":"Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy","volume":"38","author":"Millar","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/qco.0000000000000983","article-title":"A new direction for cytomegalovirus prophylaxis among transplant recipients: benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis","volume":"36","author":"Moore","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e002007","DOI":"10.1136\/openhrt-2022-002007","article-title":"Early-onset cardiac dysfunction following allogeneic haematopoietic stem cell transplantation","volume":"9","author":"Moriyama","year":"2022","journal-title":"Open Heart"},{"key":"B35","doi-asserted-by":"publisher","first-page":"105361","DOI":"10.1016\/j.antiviral.2022.105361","article-title":"First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure","volume":"204","author":"Muller","year":"2022","journal-title":"Antivir. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.mcna.2016.01.004","article-title":"Managing cardiovascular risk in the post solid organ transplant recipient","volume":"100","author":"Munagala","year":"2016","journal-title":"Med. Clinics N. Am."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e32622","DOI":"10.1016\/j.heliyon.2024.e32622","article-title":"Adaptive natural killer cell expression in response to cytomegalovirus infection in blood and solid cancer","volume":"10","author":"Okpoluaefe","year":"2024","journal-title":"Heliyon"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e61841","DOI":"10.1371\/journal.pone.0061841","article-title":"Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection","volume":"8","author":"Palaniyandi","year":"2013","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e2024065","DOI":"10.4084\/mjhid.2024.065","article-title":"Update on cytomegalovirus infection management in allogeneic hematopoietic stem cell transplant recipients. A consensus Document of the Spanish Group for hematopoietic transplantation and cell therapy (GETH-TC)","volume":"16","author":"Pi\u00f1ana","year":"2024","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/psp4.12593","article-title":"Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients","volume":"10","author":"Prohn","year":"2021","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French Compassionate Program","volume":"26","author":"Robin","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B43","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/iid3.431","article-title":"Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients","volume":"9","author":"Royston","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet. Haematol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.coviro.2020.07.013","article-title":"Cytomegalovirus as an immunomodulator across the lifespan","volume":"44","author":"Semmes","year":"2020","journal-title":"Curr. Opinion Virol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"eaax9856","DOI":"10.1126\/sciadv.aax9856","article-title":"Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function","volume":"6","author":"Sen","year":"2020","journal-title":"Sci. Adv."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2040620720937150","DOI":"10.1177\/2040620720937150","article-title":"Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant","volume":"11","author":"Shigle","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"B48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/B978-0-323-79833-4.00011-5","article-title":"11 - pharmacology of drugs used in hematopoietic cell transplant and chimeric antigen receptor therapies","volume-title":"Manual of Hematopoietic Cell Transplantation and Cellular Therapies","author":"Shigle","year":"2024"},{"key":"B49","doi-asserted-by":"publisher","first-page":"582.e1","DOI":"10.1016\/j.jtct.2025.12.995","article-title":"Letermovir prophylaxis does not hinder immune reconstitution while reshaping viral infection landscape in children","volume":"32","author":"Spadea","year":"2026","journal-title":"Transpl. Cell Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-141856","article-title":"Potent interaction between CMV reactivation and gvhd: immunologic evidence for blunting of CMV-Driven immune reconstitution in the setting of gvhd","volume":"136","author":"Suessmuth","year":"2020","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/bloodadvances.2021005509","article-title":"Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG","volume":"6","author":"Turki","year":"2022","journal-title":"Blood Adv."},{"key":"B52","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaccao.2023.07.007","article-title":"Cardiovascular events after hematopoietic stem cell transplant: incidence and risk factors","volume":"5","author":"Vasbinder","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"11785","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for Refractory\/Resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl. Int."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e13570","DOI":"10.1111\/tid.13570","article-title":"Letermovir prophylaxis in solid organ transplant-assessing CMV breakthrough and tacrolimus drug interaction","volume":"23","author":"Winstead","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/TP.0000000000003224","article-title":"Cardiac mortality in kidney transplant patients: a population-based cohort Study 1988\u20132013 in Australia and New Zealand","volume":"105","author":"Wyld","year":"2021","journal-title":"Transplantation"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1111\/bjh.19451","article-title":"Letermovir prophylaxis reduced cytomegalovirus reactivation and resistance post umbilical cord blood transplantation","volume":"204","author":"Yan","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1093\/ofid\/ofab466.020","article-title":"20. Risk Factors for breakthrough Cytomegalovirus (CMV) Infection and de novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis","volume":"8","author":"Zamora","year":"","journal-title":"Open Forum Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1935778\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:39:43Z","timestamp":1790656783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1935778\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":58,"alternative-id":["10.3389\/fphar.2026.1935778"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1935778","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1935778"}}